{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:49:35Z","timestamp":1794606575119,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immune checkpoint inhibitors targeting PD-1\/L1 have modest efficacy in hepatocellular carcinoma as single agents. Targeting membranous phosphatidylserine may induce pro-inflammatory and -immune stimulating effects that enhance immunotherapy activity. This hypothesis was tested in a single-arm phase 2 trial evaluating frontline bavituximab, a phosphatidylserine targeting antibody, plus pembrolizumab (anti-PD-1) in patients with unresectable hepatocellular carcinoma (NCT03519997). The primary endpoint was investigator-assessed objective response rate among evaluable patients, and secondary end points included progression-free survival, incidence of adverse events, overall survival, and duration of response. Among 28 evaluable patients, the confirmed response rate was 32.1%, which met the pre-specified endpoint, and the median progression-free survival was 6.3 months (95% CI, 1.3\u201311.3 months). Treatment related-adverse events of any grade occurred in 45.7% of patients, with grade 3 or greater adverse events in 14.3% of patients. Adverse events of any cause were observed in 33 patients (94.3%), with grade 3 or greater adverse events in 11 patients (31.4%). Prespecified exploratory analyses of baseline tumor specimens showed that a depletion of B cells, and the presence of fibrotic tissue and expression of immune checkpoints in stroma was associated with tumor response. These results suggest that targeting phosphatidylserine may lead to synergistic effects with PD-1 blockade without increasing toxicity rates, and future studies on this therapeutic strategy may be guided by biomarkers characterizing the pre-treatment tumor microenvironment.<\/jats:p>","DOI":"10.1038\/s41467-024-46542-y","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T12:01:49Z","timestamp":1710158509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9139-302X","authenticated-orcid":false,"given":"David","family":"Hsiehchen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad S.","family":"Beg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Kainthla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Lohrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed M.","family":"Kazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Khosama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Claire","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Kline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9323-6766","authenticated-orcid":false,"given":"Courtney","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Siglinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Youssoufian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Mockbee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Culm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Uhlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2704-2377","authenticated-orcid":false,"given":"Rolf A.","family":"Brekken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1172-3971","authenticated-orcid":false,"given":"Amit G.","family":"Singal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-9698","authenticated-orcid":false,"given":"Hao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9430-1426","authenticated-orcid":false,"given":"Yujin","family":"Hoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"Yopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"key":"46542_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang, J. D. et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 16, 589\u2013604 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"46542_CR2","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"46542_CR3","doi-asserted-by":"publisher","unstructured":"Abou-Alfa, G. K. et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. https:\/\/doi.org\/10.1056\/EVIDoa2100070 (2022).","DOI":"10.1056\/EVIDoa2100070"},{"key":"46542_CR4","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/cdd.2016.11","volume":"23","author":"RB Birge","year":"2016","unstructured":"Birge, R. B. et al. Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differ. 23, 962\u2013978 (2016).","journal-title":"Cell Death Differ."},{"key":"46542_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1146\/annurev.biophys.093008.131234","volume":"39","author":"PA Leventis","year":"2010","unstructured":"Leventis, P. A. & Grinstein, S. The distribution and function of phosphatidylserine in cellular membranes. Annu. Rev. Biophys. 39, 407\u2013427 (2010).","journal-title":"Annu. Rev. Biophys."},{"key":"46542_CR6","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2217\/imt.11.87","volume":"3","author":"P DeRose","year":"2011","unstructured":"DeRose, P., Thorpe, P. E. & Gerber, D. E. Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment. Immunotherapy 3, 933\u2013944 (2011).","journal-title":"Immunotherapy"},{"key":"46542_CR7","doi-asserted-by":"publisher","first-page":"6888","DOI":"10.1158\/1078-0432.CCR-11-1074","volume":"17","author":"DE Gerber","year":"2011","unstructured":"Gerber, D. E. et al. Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 17, 6888\u20136896 (2011).","journal-title":"Clin. Cancer Res."},{"key":"46542_CR8","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/cam4.447","volume":"4","author":"P Chalasani","year":"2015","unstructured":"Chalasani, P. et al. A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer. Cancer Med. 4, 1051\u20131059 (2015).","journal-title":"Cancer Med."},{"key":"46542_CR9","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1093\/annonc\/mdy177","volume":"29","author":"DE Gerber","year":"2018","unstructured":"Gerber, D. E. et al. Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer. Ann. Oncol. 29, 1548\u20131553 (2018).","journal-title":"Ann. Oncol."},{"key":"46542_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s11523-019-00663-3","volume":"14","author":"AA Mokdad","year":"2019","unstructured":"Mokdad, A. A. et al. Efficacy and safety of bavituximab in combination with sorafenib in advanced hepatocellular carcinoma: a single-arm, open-label, phase II clinical trial. Target Oncol. 14, 541\u2013550 (2019).","journal-title":"Target Oncol."},{"key":"46542_CR11","doi-asserted-by":"publisher","unstructured":"Huang, X., Ye, D., Brekken, R. & Yin, Y. Abstract LB-262: phosphatidylserine-targeting antibody synergizes with anti-PD-1 antibody to inhibit tumor growth in K1735 mouse melanoma model. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.am2014-lb-262 (2014).","DOI":"10.1158\/1538-7445.am2014-lb-262"},{"key":"46542_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-S3-P206","volume":"2","author":"J Gong","year":"2014","unstructured":"Gong, J. et al. Targeting of phosphatidylserine by monoclonal antibodies enhances activity of immune checkpoint inhibitors in breast tumors. J. Immunother. Cancer 2, P206 (2014).","journal-title":"J. Immunother. Cancer"},{"key":"46542_CR13","doi-asserted-by":"publisher","unstructured":"Gong, J. et al. Abstract 4978: Targeting of phosphatidylserine by monoclonal antibodies enhances activity of immune checkpoint inhibitors in tumors. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.am2014-4978 (2014).","DOI":"10.1158\/1538-7445.am2014-4978"},{"key":"46542_CR14","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1158\/1078-0432.CCR-21-3807","volume":"28","author":"G Verset","year":"2022","unstructured":"Verset, G. et al. Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase II KEYNOTE-224 trial. Clin. Cancer Res. 28, 2547\u20132554 (2022).","journal-title":"Clin. Cancer Res."},{"key":"46542_CR15","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu, A. X. et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 19, 940\u2013952 (2018).","journal-title":"Lancet Oncol."},{"key":"46542_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J. Clin. Oncol. 38, 193\u2013202 (2020).","journal-title":"J. Clin. Oncol."},{"key":"46542_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2022.40.4_suppl.383","volume":"40","author":"S Qin","year":"2022","unstructured":"Qin, S. et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study. J. Clin. Oncol. 40, 383 (2022).","journal-title":"J. Clin. Oncol."},{"key":"46542_CR18","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/hep.27222","volume":"60","author":"HB El-Serag","year":"2014","unstructured":"El-Serag, H. B. & Kanwal, F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology 60, 1767\u20131775 (2014).","journal-title":"Hepatology"},{"key":"46542_CR19","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s11901-020-00554-6","volume":"19","author":"F Ajayi","year":"2020","unstructured":"Ajayi, F., Jan, J., Singal, A. G. & Rich, N. E. Racial and sex disparities in hepatocellular carcinoma in the USA. Curr. Hepatol. Rep. 19, 462\u2013469 (2020).","journal-title":"Curr. Hepatol. Rep."},{"key":"46542_CR20","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"46542_CR21","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1373\/clinchem.2019.303644","volume":"65","author":"MJ Duffy","year":"2019","unstructured":"Duffy, M. J. & Crown, J. Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients. Clin. Chem. 65, 1228\u20131238 (2019).","journal-title":"Clin. Chem."},{"key":"46542_CR22","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1158\/1078-0432.CCR-21-3329","volume":"28","author":"R Cristescu","year":"2022","unstructured":"Cristescu, R. et al. Transcriptomic determinants of response to pembrolizumab monotherapy across solid tumor types. Clin. Cancer Res. 28, 1680\u20131689 (2022).","journal-title":"Clin. Cancer Res."},{"key":"46542_CR23","doi-asserted-by":"publisher","first-page":"1158345","DOI":"10.3389\/fonc.2023.1158345","volume":"13","author":"M Uhlik","year":"2023","unstructured":"Uhlik, M. et al. Xerna TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers. Front Oncol. 13, 1158345 (2023).","journal-title":"Front Oncol."},{"key":"46542_CR24","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng, A. L. et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. 76, 862\u2013873 (2022).","journal-title":"J. Hepatol."},{"key":"46542_CR25","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/1078-0432.CCR-21-2275","volume":"28","author":"AC Palmer","year":"2022","unstructured":"Palmer, A. C., Izar, B., Hwangbo, H. & Sorger, P. K. Predictable clinical benefits without evidence of synergy in trials of combination therapies with immune-checkpoint inhibitors. Clin. Cancer Res. 28, 368\u2013377 (2022).","journal-title":"Clin. Cancer Res."},{"key":"46542_CR26","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","volume":"171","author":"AC Palmer","year":"2017","unstructured":"Palmer, A. C. & Sorger, P. K. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell 171, 1678\u20131691.e1613 (2017).","journal-title":"Cell"},{"key":"46542_CR27","doi-asserted-by":"publisher","unstructured":"Mu, X. M., Wang, W., Jiang, Y. Y. & Feng, J. Patterns of comorbidity in hepatocellular carcinoma: a network perspective. Int. J. Environ. Res. Public Health. https:\/\/doi.org\/10.3390\/ijerph17093108 (2020).","DOI":"10.3390\/ijerph17093108"},{"key":"46542_CR28","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"46542_CR29","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556\u2013560 (2020).","journal-title":"Nature"},{"key":"46542_CR30","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"46542_CR31","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","volume":"2","author":"WJ Ho","year":"2021","unstructured":"Ho, W. J. et al. Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. Nat. Cancer 2, 891\u2013903 (2021).","journal-title":"Nat. Cancer"},{"key":"46542_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00460-1","volume":"11","author":"E Zhang","year":"2023","unstructured":"Zhang, E. et al. Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy. Biomark. Res. 11, 28 (2023).","journal-title":"Biomark. Res."},{"key":"46542_CR33","doi-asserted-by":"publisher","first-page":"e0169755","DOI":"10.1371\/journal.pone.0169755","volume":"12","author":"R Audo","year":"2017","unstructured":"Audo, R. et al. Phosphatidylserine outer layer translocation is implicated in IL-10 secretion by human regulatory B cells. PLoS ONE 12, e0169755 (2017).","journal-title":"PLoS ONE"},{"key":"46542_CR34","doi-asserted-by":"publisher","first-page":"108620","DOI":"10.1016\/j.celrep.2020.108620","volume":"34","author":"S Budhu","year":"2021","unstructured":"Budhu, S. et al. Targeting phosphatidylserine enhances the anti-tumor response to tumor-directed radiation therapy in a preclinical model of melanoma. Cell Rep. 34, 108620 (2021).","journal-title":"Cell Rep."},{"key":"46542_CR35","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu, A. X. et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat. Med. 28, 1599\u20131611 (2022).","journal-title":"Nat. Med."},{"key":"46542_CR36","doi-asserted-by":"publisher","unstructured":"Barrett, R. L. & Pure, E. Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy. Elife. https:\/\/doi.org\/10.7554\/eLife.57243 (2020).","DOI":"10.7554\/eLife.57243"},{"key":"46542_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.imbio.2013.06.008","volume":"219","author":"TA Curran","year":"2014","unstructured":"Curran, T. A., Jalili, R. B., Farrokhi, A. & Ghahary, A. IDO expressing fibroblasts promote the expansion of antigen specific regulatory T cells. Immunobiology 219, 17\u201324 (2014).","journal-title":"Immunobiology"},{"key":"46542_CR38","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/S0168-8278(96)80267-4","volume":"24","author":"T Terada","year":"1996","unstructured":"Terada, T., Makimoto, K., Terayama, N., Suzuki, Y. & Nakanuma, Y. Alpha-smooth muscle actin-positive stromal cells in cholangiocarcinomas, hepatocellular carcinomas and metastatic liver carcinomas. J. Hepatol. 24, 706\u2013712 (1996).","journal-title":"J. Hepatol."},{"key":"46542_CR39","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/hep.1840190415","volume":"19","author":"H Enzan","year":"1994","unstructured":"Enzan, H. et al. Alpha-smooth muscle actin-positive perisinusoidal stromal cells in human hepatocellular carcinoma. Hepatology 19, 895\u2013903 (1994).","journal-title":"Hepatology"},{"key":"46542_CR40","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3892\/ol.2013.1720","volume":"7","author":"JG Parikh","year":"2014","unstructured":"Parikh, J. G., Kulkarni, A. & Johns, C. alpha-smooth muscle actin-positive fibroblasts correlate with poor survival in hepatocellular carcinoma. Oncol. Lett. 7, 573\u2013575 (2014).","journal-title":"Oncol. Lett."},{"key":"46542_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adh8005","volume":"15","author":"BH Herzog","year":"2023","unstructured":"Herzog, B. H. et al. Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non-small cell lung cancer. Sci. Transl. Med. 15, eadh8005 (2023).","journal-title":"Sci. Transl. Med."},{"key":"46542_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1053\/j.gastro.2022.03.015","volume":"163","author":"J Jan","year":"2022","unstructured":"Jan, J. et al. Gender, age, racial and ethnic disparities in clinical trial enrollment for primary liver cancer. Gastroenterology 163, 14\u201320.e12 (2022).","journal-title":"Gastroenterology"},{"key":"46542_CR43","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41587-020-0472-9","volume":"38","author":"CR Merritt","year":"2020","unstructured":"Merritt, C. R. et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat. Biotechnol. 38, 586\u2013599 (2020).","journal-title":"Nat. Biotechnol."},{"key":"46542_CR44","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1200\/JCO.21.01801","volume":"40","author":"S Fu","year":"2022","unstructured":"Fu, S. et al. Phase Ib study of navicixizumab plus paclitaxel in patients with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 40, 2568\u20132577 (2022).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46542-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46542-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46542-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T02:51:20Z","timestamp":1731552680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-46542-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["46542"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-46542-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"assertion":[{"value":"20 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.H. has served as a consultant for AztraZeneca. M.S.B. is an employee of Science37. H.Y., C.M., K.C., M.U., and L.B. are employees of OncXerna Therapeutics. A.S. has served as a consultant or on advisory boards for Genentech, AztraZeneca, Eisai, Exelixis, Bayer, Boston Scientific, FujiFilm Medical Sciences, Exact Sciences, Roche, Glycotest, Universal Dx, Freenome, and GRAIL. Y.H. has served as a consultant or on advisory boards for Helio Genomics, Alentis Therapeutics, Espervita Therapeutics, and Roche Diagnostics, and holds shares in Alentis Therapeutics and Espervita Therapeutics. R.A.B. received research support from OncXerna. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2178"}}